about
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyDistribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale.Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureTransdermal rotigotine for the perioperative management of Parkinson's disease.A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need.Restless legs syndrome and PD: a review of the evidence for a possible association.The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project.Is levodopa toxic?Fall-related activity avoidance in relation to a history of falls or near falls, fear of falling and disease severity in people with Parkinson's disease.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsLevodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based reviewIntegrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.The challenge of non-motor symptoms in Parkinson's disease.What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?Parkinson's disease: the non-motor issues.Wearing-off scales in Parkinson's disease: critique and recommendations.Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.Factors Contributing to Perceived Walking Difficulties in People with Parkinson's Disease.A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.Device-Aided Treatment Strategies in Advanced Parkinson's Disease.Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's diseaseCorrection: A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need.The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire.Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications.Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.Reduced body mass index in Parkinson's disease: contribution of comorbid depression.Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS).Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
P50
Q30366253-15AE9EAC-2CF1-4DCE-A3B0-7D573A265CFFQ33766006-B386F65B-B715-422B-9474-0C5B748A4C47Q33917283-5B4CD03D-280E-40AB-9834-46722FC9D042Q33956617-817A2C33-73D7-4D2C-B242-FBF153DD68D4Q34611889-CDA367E0-AF4F-462F-892E-CB350A86B967Q35540923-9664538B-4EC2-4BFD-8CD8-C52E30243E3CQ35608939-70A8D248-AF5A-452E-B5A1-04DA4454B084Q36022114-FA31CE3F-7BA7-4A46-B33F-77E5A7064EDCQ36037102-9F232F88-CB1B-4D18-9738-D59A2D9D8BD0Q36361513-BDB3E5EB-C071-4318-AF66-84B25B5CC58DQ36866618-DF45727C-093F-449E-975F-1F6690D9EBCDQ36910602-AFE298A0-E4A9-492C-9EE7-8DB87040D354Q37302240-1D1D773B-50ED-4539-9DBC-55B73C92B0D2Q37340428-117E9E4A-795C-4E56-91DE-6691D4A4BA7CQ37678381-B3126331-1676-4B3D-84D4-F7EDE2A3EE51Q37685701-8EDDF077-E837-4CB6-B79C-A7C23CDA2E33Q37796036-1FCEDD1B-A11D-4426-B91B-78A3C1138292Q37824279-3F27E972-FD01-44D1-860E-CDA96465ECD9Q37899473-056D48CD-4C1D-4E8B-A7D0-3D8F474AD43DQ37903795-B3B78AB8-C7E5-4117-8AF9-6750F9EC3BF9Q38085905-616B87E9-07F5-4538-9900-9E6C780557B7Q38550141-A270FAFA-5C46-4FBE-9F94-4C4D8FD77E31Q38683677-970BE658-9A7D-4C74-8B11-7FA78B1EFDD4Q38697121-69851818-213E-4F13-9B7D-F4BAAD18F744Q38823793-76523536-67F8-4026-A0BC-0A0DD7A0CD74Q38858248-082C664D-624F-4F3C-B8F4-7F2692A9D44AQ40195332-AA31BB5C-DA9E-4F5E-ABDA-92DB7C93D2B7Q41055649-D7473311-C5CC-4BD9-837D-2C304A2935DBQ42582187-F0077792-B749-403F-8917-682A85026517Q43649463-80BD0222-1DDD-48FD-9D39-A28071F6E710Q44057380-88DB8EF4-4164-4F2E-A007-258C79635D92Q44113277-8FAE8C7B-0554-455E-986D-DFB9FBB0EA3AQ45130573-08DACF25-9407-4B93-A676-6BC2E0F80043Q46043137-E7F51B53-5333-44EE-B78E-7287399D9135Q46565350-125E4D90-6CD0-4FC4-B316-5F554116E6C5Q46784811-4FE37F8D-F1F1-4820-AFB2-DE62148CFC34Q46895728-A75721F2-CD06-462E-B52D-0C79C64DB0BDQ47439681-AA01BD86-305C-42E6-96D5-8E77B1814289Q47652358-AF7CB481-5321-47E2-AA9D-B6FB800B753CQ47666154-6AA54F61-640E-4A4F-86CA-7E68FA6D5A55
P50
name
Per Odin
@ast
Per Odin
@en
Per Odin
@nl
type
label
Per Odin
@ast
Per Odin
@en
Per Odin
@nl
prefLabel
Per Odin
@ast
Per Odin
@en
Per Odin
@nl
P214
P214
P31
P7859
lccn-n2004123880